Longitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients (LET-PKD Study).
Phase of Trial: Phase IV
Latest Information Update: 11 Mar 2017
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms LET-PKD
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned primary completion date changed from 1 Apr 2019 to 31 Mar 2017.
- 01 Nov 2016 Status changed from not yet recruiting to recruiting.